Antihypertensives and myocardial infarction risk: the modifying effect of history of drug use
- 1 June 2001
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 10 (4) , 287-294
- https://doi.org/10.1002/pds.595
Abstract
Purpose Confounding by indication is common in observational studies of outcomes that treatment is intended to affect. In light of the stepped‐care approach to hypertension management, we reexamined the controversy around myocardial infarction (MI) risk in relation to antihypertensive agents by considering past drug history both as a confounder and as an effect modifier. Methods Case–control design nested within a cohort of 19 501 adults initiating therapy with angiotensin‐converting enzyme inhibitors (ACEI), calcium channel blockers (CCB) or β‐blockers in Saskatchewan (1990–93) and followed up to 1997. MI cases were identified using death certificates and hospital discharge diagnoses (ICD‐9 410). Four controls were matched to each case to account for duration and timing of follow‐up. Results 812 MI cases were identified, of which 26% were fatal. At first, current use of CCB and ACEI (versus β‐blockers) appeared to be associated with an increased risk of MI (RR = 2.2; 95% CI = 1.8–2.7 and RR = 1.3; CI = 1.0–1.6 respectively). Adjustment for drug use history attenuated both associations (RR = 1.6; CI = 1.1–2.2 and RR = 1.0; CI = 0.7–1.4). Moreover, the risk for CCB use disappeared when restricted to patients who had already used these agents in the past (RR = 1.1; CI = 0.77–1.7) whereas a high risk of MI for ACEI was found in digoxin users (RR = 9.4; CI = 3.2–27.5). Conclusion Past drug history can be both a confounder and an effect modifier in observational studies. We found adjustment for medication history to attenuate the associations between antihypertensive agents and MI risk. In addition, the estimates significantly varied across drug history profiles thus suggesting the presence of preferential prescribing of specific drug classes to high‐risk patients. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- Using medication history to measure confounding by indication in assessing calcium channel blockers and other antihypertensive therapyJournal of Human Hypertension, 2001
- Prospective Study of Calcium Channel Blocker Use, Cardiovascular Disease, and Total Mortality Among Hypertensive WomenCirculation, 1998
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureArchives of internal medicine (1960), 1997
- Myocardial Infarction in Newly Diagnosed Hypertensive Medicaid Patients Free of Coronary Heart Disease and Treated with Calcium Channel BlockersThe American Journal of Medicine, 1997
- Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertensionEuropean Heart Journal, 1996
- Necrobacillosis: are we missing the early stages of this life-threatening infection?The Lancet, 1995
- Long‐Term Survival and Use of Antihypertensive Medications in Older PersonsJournal of the American Geriatrics Society, 1995
- Calcium Channel Blockers and Myocardial InfarctionJAMA, 1995
- The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)Archives of internal medicine (1960), 1993
- Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactionsJournal of Clinical Epidemiology, 1989